The FDA is ordering makers of brand-name and generic sedative-hypnotic drugs, or insomnia treatments with active ingredient zolpidem, to reduce dosages for women. Studies find that high levels of the drugs remain in the bloodstream, which can raise the risk of car accidents by affecting coordination and alertness. Dosages for regular products should be lowered from 10 milligrams to 5 milligrams, while dosages for extended-release formulations should be reduced from 12.5 milligrams to 6.25 milligrams.